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The deficit of human ornithine aminotransferase (hOAT) is responsible for gyrate atrophy
(GA), a rare recessive inherited disorder. Although more than 60 disease-associated
mutations have been identified to date, the molecular mechanisms explaining how each
mutation leads to the deficit of OAT are mostly unknown. To fill this gap, we considered six
representative missense mutations present in homozygous patients concerning residues
spread over the hOAT structure. E. coli expression, spectroscopic, kinetic and
bioinformatic analyses, reveal that the R154L and G237D mutations induce a catalytic
more than a folding defect, the Q90E and R271K mutations mainly impact folding
efficiency, while the E318K and C394Y mutations give rise to both folding and catalytic
defects. In a human cellular model of disease folding-defective variants, although at a
different extent, display reduced protein levels and/or specific activity, due to increased
aggregation and/or degradation propensity. The supplementation with Vitamin B6, to
mimic a treatment strategy available for GA patients, does not significantly improve the
expression/activity of folding-defective variants, in contrast with the clinical responsiveness
of patients bearing the E318K mutation. Thus, we speculate that the action of vitamin B6
could be also independent of hOAT. Overall, these data represent a further effort toward a
comprehensive analysis of GA pathogenesis at molecular and cellular level, with important
relapses for the improvement of genotype/phenotype correlations and the development of
novel treatments.
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INTRODUCTION
Human ornithine aminotransferase (hOAT) is a pyridoxal 5′-
phosphate (PLP)-dependent enzyme localized in the
mitochondrial matrix, that catalyzes the δ-transamination of
L-ornithine (L-Orn) and α-ketoglutarate (αKG) to glutamic-
γ-semialdehyde and L-glutamate. The spontaneous cyclization
of glutamic-γ-semialdehyde then generates the proline precursor
pyrroline-5-carboxylate (P5C). The enzyme has a prominent role
in L-Orn degradation and in proline synthesis, although some
evidences also indicate its involvement in cell cycle regulation (Liu
et al., 2019). The 439-residues chain of the hOAT precursor is
encoded by the OAT gene located on chromosome 10p26, and then
processed after cleavage of the mitochondrial targeting sequence to
the mature protein (Inana et al., 1986). hOAT belongs to the Fold
Type I family of PLP-enzymes (Shen et al., 1998) and in solution
assembles as a tight homotetramer formed by two dimers that
constitute the minimal functional unit of the enzyme (Montioli
et al., 2017). Each subunit includes an N-terminal segment
wrapping over the neighboring subunit, a large domain
(residues 95–344) comprising the active site region and most of
the subunit interface, and a C-terminal small domain (Shen et al.,
1998). The active site lies at the junction between the two subunits
of the dimer. PLP is bound through a Schiff base linkage with
Lys292 and stabilized through hydrogen bonds, salt bridges and
hydrophobic interactions with residues belonging to both subunits.
The cofactor also exerts a structural role for hOAT, by promoting
tetramerization and reducing the tendency to unfolding and
aggregation typical of the apo-form (Montioli et al., 2017).
Inherited mutations on the OAT gene lead to gyrate atrophy of
the choroid and retina (GA), a rare recessive disease characterized by
the degeneration of the choroid and the retinal epithelium. Patients
develop myopia during childhood, and show a progressive decrease
in visual acuity from the 2° to the 3° decade leading to blindness
within the 5° decade (Simell and Takki, 1973). In most GA patients
cognition is unaffected (Wang et al., 2000). The deficit of hOAT leads
to a 10-to-15 fold increase in the plasmatic L-Orn concentration,
along with a small reduction in the levels of glutamate, glutamine,
lysine and creatine (Valle et al., 1980; Hasanoglu et al., 1996). It is
currently assumed that retinal damage is due to hyperornithinemia
and to the increase in ornithine degradation products (Kaneko et al.,
2007; Ohnaka et al., 2011), although the molecular mechanisms of
GA pathophysiology are still unclear. No effective therapies are
currently available, except for dietary restriction, which aims at
reducing ornithine burden, and Vitamin B6 administration,
which aims at increasing the plasmatic PLP concentration
(Kennaway et al., 1980; Ramesh et al., 1988; Kennaway et al.,
1989; Heller et al., 2017; Montioli et al., 2021).
The genetic cause of GA is known since 1973 (Simell and
Takki, 1973), and 68 different disease-causing mutations in the
OAT gene are currently deposited in the HGMD database, being
missense changes the most common ones. To date, only two
pathogenic variants have been characterized at protein level and/
or in human cellular models of disease, revealing opposite
molecular defects: the V332M, endowed with an unaltered
intrinsic catalytic activity but affected by a folding defect that
strongly reduces the intracellular levels of functional enzyme
(Montioli et al., 2018), and the R180T, showing an altered
structure but an almost complete loss of transaminase activity
(Montioli et al., 2019). Considering that most disease-causing
missense mutations involve residues that are spread over the
enzyme structure, further investigations on the defect(s) caused
by pathogenic mutations in hOAT would represent a useful tool
toward a better understanding of GA pathogenesis. To this aim,
we retrieved pathogenic mutations present in homozygous
patients or in compound heterozygous with null mutations
(Supplementary Table S1) and we specifically focused on
mutations affecting 1) Gln90 of the N-terminal region, 2)
Arg154, Arg271, Glu318 and Gly237 of the large domain, 3)
Cys394 of the C-terminal small domain (Figure 1A).
We combined biochemical and bioinformatic analyses on the
purified recombinant Q90E, R154L, G237D, R271K, E318K, and
C394Y variants with expression studies in prokaryotic and
eukaryotic cells. From our investigations, we deduced that 1) the
R154L andG237D variants exhibit a dramatic loss of catalytic activity
accompanied by a modest folding defect, 2) the Q90E and R271K
variants display a remarkable folding defect responsible for increased
degradation propensity, and 3) the E318K and C394Y variants show
both catalytic and folding defects. In addition, we noticed that
treatment of the folding-defective variants with Vitamin B6 does
not significantly improve their expression levels and specific activity,
possibly suggesting that effects unrelated to hOAT could be
responsible for the clinical responsiveness of the patients.
MATERIALS AND METHODS
Materials
L-Orn, α-KG, 2-aminobenzaldehyde, dimethyl sulphoxide,
isopropyl-β-D-thiogalactoside, pyridoxine (PN), pyridoxamine
(PM), pyridoxal (PL) were purchased from Sigma-Aldrich. 1,8-
anilino-naphthalene sulfonic acid (ANS) was purchased from
Molecular Probes. Growth media and additives were purchased
from Gibco. PEGylated bis (sulfosuccinimidyl) suberate [BS
(PEG) 5] was purchased from ThermoFisher. All other
chemicals were of the highest purity available.
Vector Construction
The vectors encoding the analyzed hOAT variants were obtained
from the pOAT and the pLENTI6CMV-DEST vectors previously
used for the prokaryotic and mammalian expression of hOAT,
respectively (Montioli et al., 2017; Montioli et al., 2018). Each
mutation was introduced by the QuikChange II site-directed
mutagenesis kit (Agilent Technologies) using Pfu-Ultra
polymerase and the oligonucleotides listed in Supplementary
Table S2. All the mutations were confirmed by DNA sequence
analysis of the entire ORF.
In Silico Studies
Structural position and possible contacts of each mutated residue
were evaluated by the PyMol software starting from the available
crystal structure of hOAT (pdb file 1OAT). The in silico
mutagenesis tool of PyMol was used to obtain the initial
mutant structures. An energy minimization process in explicit
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solvent was carried out on the hOAT structure before and after
the mutagenesis using the GROMACS v4.6.3 software. The Q90E,
R271K, E318K and C394Y model structures underwent two
minimization steps (with and without restraints), alternating
Steepest Descent and Conjugate Gradient algorithms.
Expression and Purification of Mutants
hOAT variants were expressed in E. coli and the cell lysate was
treated as previously described (Montioli et al., 2017). The soluble
fraction was loaded on a DEAE Sepharose 26/20 equilibrated with
20 mM sodium phosphate buffer, pH 7.6. A linear gradient from
20 to 180 mM sodium phosphate buffer, pH 7.6, was then applied.
Under these conditions, OAT wild-type and all the pathogenic
variants elute from the column between 110 and 160 mM sodium
phosphate. Active fractions were then concentrated using an
Amicon Ultra 15 unit (Millipore) and applied to a Superdex
200 XK 16/60 column (GE Healthcare) equilibrated in 50 mM
HEPES, pH 7.4, NaCl 200 mM. Purified protein was concentrated
and stored at −20°C. The purity of each preparation assessed by
SDS-PAGE was >95%. The final yield of OATWT, Q90E, R154L,
G237D, R271K, E318K and C394Y variants were 35, 4, 26, 24, 7,
11 and 8 mg/L of liquid culture, respectively.
Enzyme Activity Assays
hOAT activity was determined by a spectrophotometric assay
based on the measurement of the dihydroquinazolium derivative
of P5C after incubation with 2-aminobenzaldehyde as previously
described (Montioli et al., 2017). The kinetic parameters for the
overall transamination of the pair L-Orn/αKG were determined
by incubating the purified protein in the presence of 100 µM PLP
and by varying the substrate concentration at a fixed saturating
cosubstrate concentration. Data were fitted to the Michaelis-
Menten equation. In the case of the C394Y variant, data were




(1 + (KMS ) + ( SKi))
(1)
where Et is the total enzyme concentration, kcat the maximum
velocity, S the substrate concentration, KM the apparent
FIGURE 1 | Overview of the mutation sites on the hOAT dimer. Ribbons representation of the OAT dimer; monomers are colored white and blue respectively, the
residues subjected to mutation are highlighted in yellow and PLP molecules are represented as green sticks. (A) Global distribution of the mutation sites on OAT.
Microenvironment and contacts of (B) Gln90/Arg271, (C) Arg154, (D) Gly237, (E) Glu318 and (F) Cys394 residues. *denotes residues belonging to the neighboring
subunits. Image was rendered by Pymol software (Schrödinger).
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Michaelis-Menten constant, and Ki the dissociation constant for
the inhibitory ternary complex. To measure the intracellular
hOAT transaminase activity, 100 μg of the soluble cellular
lysate were incubated in 50 mM HEPES, pH 8.0, 150 mM
NaCl and 100 μM PLP at 25°C with saturating concentration
of L-Orn (100 mM) and α-KG (50 mM) for 15–60 min.
Spectroscopic Measurements
Absorbance, Near-UV CD and fluorescence measurements were
carried out in 50mM HEPES containing 150mM NaCl, pH 8.0,
Far-UV CD spectra were registered in 10mM HEPES pH 8.0, plus
15mMNaCl. All measurements were performed at 25°C. Absorption
measurements weremadewith a JascoV-550 spectrophotometer with
a 1 cm path length quartz cuvettes at a protein concentration of 6 µM.
Near-UV and visible CD spectra were recorded in the presence of
20 μM PLP on a Jasco J-710 spectropolarimeter equipped with a
thermostatically controlled compartment at 25°C by using 1 cm path-
length quartz cuvettes at protein concentrations between 5 and 10 μM.
Routinely, three spectra were recorded at a scan speed of 50 nm/min
with a bandwidth of 2 nm and averaged automatically. For far-UV
measurements, the protein concentrationwas 1 μMwith a path length
of 0.1 cm. Fluorescence measurements were made with a FP750 Jasco
spectrofluorimeter at a protein concentration of 1 μM in the presence
of 10 µM PLP. ANS emission spectra were registered upon excitation
at 365 nmof a 1 μMenzyme sample previously incubatedwith 20 μM
ANS for 1 h on ice in the presence of 10 µM PLP.
Size-Exclusion Chromatography
SEC experiments were performed using an AktaPure FPLC
system (GE Healthcare) and a Superdex 200 Increase 10/
300 GL column equilibrated and run in 50 mM HEPES pH
8.0, containing 150 mM NaCl and 20 μM PLP. Each variant
was dissolved in the running buffer at a concentration of
10 μM and incubated for 20 min at 25°C. Then, 0.1 ml of
sample were loaded on the column and eluted at a flow rate
of 0.5 ml/min. Chromatographic profiles were analyzed by the
Unicorn v7.3 software (GE Healthcare).
Limited Proteolysis
hOAT wild-type or the Q90E, R271K, E318K and C394Y variants
were incubated with proteinase K at a 1:100 protease/enzyme
ratio (w/w) at 25°C in PBS buffer pH 8.0 in the presence of 20 μM
PLP. Aliquots were withdrawn at different times and treated with
2 mM PMSF. Five micrograms of each sample were loaded on a
12% SDS-PAGE gel.
Cell Culture and Lysis
Hek293 cells knock-out for the OAT gene (Hek293-OAT_KO)
cells were cultured in DMEM supplemented with 10% fetal
bovine serum, glutamine (4 mM), penicillin (100 units/ml) and
streptomycin (100 μg/ml) at 37°C in a humidified 5% CO2
environment. For lentiviral-based stable expression of hOAT
forms, Hek293-OAT_KO cells were infected with lentiviral
particles containing pLENTI6CMV-DEST vectors encoding
each species and selected with 5 mg/ml hygromycin for
construct integration into the genome.
To test the effect of PN, PL and PM, cells were cultured in Petri
dishes in Ham’s F12 Glutamax medium in the absence or
presence of 10 μM of each vitamer for 4 days. In each
experiment, cells were harvested and lysed in CHAPS buffer
(1% w/v CHAPS, 100 mM KCl, 20 mM HEPES, 1 mM EGTA),
pH 8.0 plus protease inhibitor cocktail (Complete Mini, Roche)
and 100 μM PLP for 30 min on ice. The whole cell extract was
separated by centrifugation (29,200 g, 10 min, 4°C) to obtain the
soluble fraction. The pellets were then resuspended in an equal
volume of denaturing gel loading buffer to obtain the insoluble
fraction. Protein concentration in the soluble cell lysate was
measured using the Bradford assay.
Blue Native Page
Mitochondrial isolation was carried out by sequential
centrifugation. In brief, cultured cells were collected using a
scraper and centrifuged for 10 min at 600 g in PBS. The pellet
was homogenized using a Teflon pestle operated at 1,600 rpm on
ice. The homogenate was centrifuged at 600 g for 10 min. The
supernatant was centrifuged at 7,000 g for 10 min. The pellet was
resuspended with 200 μl of ice-cold isolation buffer and subjected
to a last centrifugation step for 10 min at 7,000 g. All
centrifugation steps were carried out at 4°C. Buffer
composition and other technical details can be found in
Frezza C. et al. (Doimo et al., 2013). Mitochondrial pellets
were suspended in an appropriate volume of Native Buffer
(Invitrogen) with Digitonin or DDM (Sigma-Aldrich) to a
final concentration of 1% (w/v) and membrane proteins were
solubilized during 1 h incubation on ice. After a 20 min
centrifugation at 16,000 g, the supernatant was collected and
5% G250 (Invitrogen) was added to obtain a final
concentration equal to one-quarter that of the detergent.
100–150 μg of mitochondrial membrane proteins were applied
and run on a 3–12% Bis-Tris gel (Invitrogen) and visualized using
Coomassie staining.
Western-Blot
10–20 μg of the soluble or insoluble fraction of the cell lysate were
loaded on a 10% SDS-PAGE gel, transferred on a nitrocellulose
membrane and immunoblotted with anti hOAT antibody (1:
1,000, OriGene Technologies Inc.) and horseradish peroxidase-
conjugated anti-IgG antibody (1:5,000). GAPDH (1:100, Cell
Signaling Technology) antibody was used as marker protein
for total and soluble extracts while porin (1:2,000, AbCam)
was used as marker for mitochondrial extracts.
Immunocomplexes were visualized by an enhanced
chemiluminescence kit (ECL, Pierce Biotechnology, Rockford,
IL). For cross-linking experiments 25 µg of the whole cellular
lysate was treated with BS(PEG)5 at 1 mM or 10 mM final
concentrations, and quenched in 0.5 M Tris-HCl pH 7.5 after
30 min 20 µg of each sample were analyzed by western blot.
Measurement of protein half-lives by cycloheximide chase assays
were performed as described in (Montioli et al., 2013). Briefly,
Hek293-OAT_KO cells expressing each analyzed species were
treated with cycloheximide (final concentration 10 mg/ml). At
different times (0, 8, 12, 24 and 48 h) cells were harvested, lysed,
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and OAT levels were measured by western-blot, as
described above.
Immunofluorescence Microscopy
Hek293-OAT_KO cells expressing hOAT wild-type and the
Q90E variant were seeded into a 24-well plate containing a
13 mm glass cover-slip and grown for 24 h at 37°C under O2/
CO2(19:1). Cells were incubated with Mitotraker Red at 37°C for
30 min. Cells were fixed in methanol, permeabilized with 0.3%
Triton X-100 in PBS and then blocked in 3% bovine serum
albumin, 1% glycine in PBS. For immunolabeling, mouse anti-
hOAT (Acris Antibodies, 1:50) was used as primary antibody,
and Alexa Fluor conjugated antibodies (Life Technologies) were
used as secondary antibodies. Nuclei were stained with Dapi, and
the coverslips were mounted over slides in AF1 medium (Dako).
Images were captured using a Zeiss Axio Observer Z1 equipped
with Apotomeanddigital Camera AxiocamMRm (Zeiss). For




To gain insights into the possible structural and/or functional
effects of each amino acid substitution, we carried out a
preliminary inspection of the microenvironment of each
mutation site (Figure 1) followed by an in silico mutagenesis
study (Supplementary Figure S1). Gln90 lies on the loop 75–95
and contacts the backbone of Ala293 and Asn89 by two hydrogen
bonds (Figure 1B). The substitution of Gln90 with Glu probably
changes the local conformation of the loop 75–95 since it would
eliminate the possibility to form a hydrogen bond with Ala293
(Supplementary Figure S1A). Arg154 is located at themonomer/
monomer interface of the dimeric unit and close to the dimer-
dimer contact surface of the tetrameric unit of hOAT. It is in a
proper position to contact Pro202 of the same subunit and both
Pro199 and Phe197 of the neighboring subunit. The substitution
Arg154-to-Leu is predicted to both abolish the aforementioned
contacts and affect the conformation of the interface loop
195–203 (Supplementary Figure S1B). Gly237 belongs to the
loop 229–245 containing Glu235. Crystallographic studies
indicate that Glu235 could play a key role in guiding the
ω-transaminase reaction toward L-Orn by shielding Arg413
from interacting with the α-carboxylate group (Storici et al.,
1999). The in silico mutagenesis analysis (Supplementary
Figure S1C), suggests that the G237D substitution could alter
the 234–238 active site loop conformation, thus indirectly
interfering with the position of Glu235. Arg271, located into a
polar cleft, acts as a bridge between the N-terminal region and the
C-terminal domain and its side chain interacts with both the
Asn89 side chain and the Pro413 backbone oxygen (Figure 1B).
The substitution Arg271-to-Lys probably makes the residue
unable to support both interactions (Supplementary Figure
S1D) leading to a possible impact on the tertiary structure.
Glu318 is exposed on a surface region and interacts with the
side chain of Lys155 through a salt bridge (Figure 1E). Such a
contact is expected to be an important anchoring point for the
loop 313–327, which goes through the active site of the
neighboring subunit and contributes to PLP binding through
Thr322 (Supplementary Figure S1E). The substituted amino
acid, although is not predicted to give rise to remarkable
alterations, could assume a different rotameric conformation
or change the surface electrostatic potential. Lastly, Cys394 lies
on the helix 390–400 of the C-terminal domain in a position
suitable to contact the backbone oxygen of Ala404 by a hydrogen
bond (Figure 1F). The substitution of Cys394-to-Tyr possibly
abolishes the contact with Ala404 and introduces a steric
hindrance between the C-terminal and the N-terminal
domain. This is predicted to alter the conformation of the
C-terminal loop 400–411 and of the N-terminal loop 50–63,
both located at the entrance of the active site (Supplementary
Figure S1F).
Expression Studies of the Q90E, R154L,
G237D, R271K, E318K, and C394Y Variants
in E. coli
To provide insights into the structural and/or functional effect of
the selected amino acid substitutions in hOAT, we inserted each
mutation on the protein cDNA cloned in a prokaryotic
expression vector by site-directed mutagenesis. We then
compared expression level and specific activity of each variant
with that of the wild-type in E. coli cultures. As shown in
Supplementary Figure S2A, the selected variants showed
different behaviors suggesting the presence of different defects.
Two out of six mutations (Q90E, R271K) decreased at similar
extents both specific activity and soluble protein levels in western-
blot. Although the absence of a catalytic impairment cannot be
ruled out, the data suggest that these variants are endowed with a
folding defect that reduces protein levels by promoting
aggregation and/or degradation. Both the E318K and the
C394Y variants showed a reduction in specific activity more
pronounced that the reduction in soluble protein levels, a
finding that does not allow to rule out a catalytic defect along
with a possible structural impairment. In the case of the E318K,
soluble protein levels were unaltered and residual specific activity
was 49%, in line with results in yeast expression systems
evidencing that the E318K mutation caused mild effects in
terms of hOAT expression and functionality (Doimo et al.,
2013). Finally, the R154L and G237D mutations strongly
affected hOAT specific activity, but the reduction was not
accompanied by significant changes of the levels of soluble
protein. Thus, it can be envisaged that the R154L and G237D
variants are mainly affected by a catalytic defect. In line with these
results, the R154L variant was found to produce normal amounts
of expressed protein but undetectable enzymatic activity in
patient fibroblasts and in transfected mammalian cells (Brody
et al., 1992). Similarly, the hOAT enzymatic activity in cells of a
patient bearing the G237D mutation resulted undetectable
(Mashima et al., 1992; Ohkubo et al., 2005). In line with these
results, a qualitative analysis of insoluble fraction of the bacterial
lysate (Supplementary Figure S2B) shows an increased presence
of high MW species only in cells expressing the Q90E, R271K,
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E318K, and C394Y variants, suggesting that these species could
be more prone to misfolding, which in bacterial cells usually
drives aggregation in inclusion bodies. Therefore, considering
that the expression in E. coli offers the possibility to produce and
purify sufficient quantities of the examined variants, although at
different extents, we followed this approach to have a more deep
knowledge of their structural and catalytic features.
Biochemical Studies of the Purified
Recombinant Q90E, R154L, G237D, R271K,
E318K, and C394Y Variants
All variants were homogenous as indicated by a single band in
SDS-PAGE. However, the G237D variant exhibited a mobility
slightly slower with respect to the other species (Supplementary
Figure S3A). Maldi-TOF mass spectrometry analysis of this
variant yielded a molecular weight difference of 72.8 Da as
compared with the wild-type (Supplementary Figure S4), a
value compatible with the substitution of glycine with aspartic
acid. Thus, this abnormal SDS-PAGE migration can be due to a
mechanism of “gel shifting,” already observed for a set of cytosolic
proteins (Shi et al., 2012). Moreover, the overall shape of the far-
UV CD spectra of the variants were identical to that of wild-type
hOAT indicating that the mutations do not affect the secondary
structure of the protein Supplementary Figures S3B,C). To
evaluate the impact of the examined mutations on catalytic
activity, the steady-state kinetic parameters for the overall
transamination of the L-Orn/αKG pair were measured and
compared with those of wild-type hOAT (Table1). The Q90E,
R271K, and E318K variants did not show biologically meaningful
reductions of the kcat/Km values, thus indicating that the mutation
of Gln90, Arg271, or Glu318 does not cause a catalytic defect. A
special mention should be made for the C394Y variant that
displayed 1) an increased Km for α-KG leading to a∼45-fold
decrease of catalytic efficiency with respect to wild-type hOAT,
and 2) a substrate inhibition kinetics in the presence of increasing
L-Orn concentrations giving a Ki equal to 9.7 ± 1.4 mM
(Supplementary Figure S5). The kinetic parameters of this
variant have been determined using a minimal steady-state
model related to the formation of an unproductive enzyme-
substrate complex after the simultaneous binding of two or
more substrate molecules at the active site. Nevertheless, the
structural bases of this behaviour are currently unknown.
Conversely, the R154L and G237D variants exhibited a
dramatic decrease of catalytic activity with respect to the wild
type. Their kinetic parameters were difficult to obtain because of
the very slow reaction rate. In fact, when 3 µM R154L or G237D
variant was allowed to react with 100 mM L-Orn and 100 mM
α-KG, P5C was produced with an initial rate of about 0.1 and
0.08 s−1, respectively. Assuming that these values are close to their
kcat values of the transamination, the rate of the reaction of the
R154L and G237D variants is about 350- and 437-fold lower,
respectively, than that of the wild-type enzyme. These data are
compatible with what suggested by the computational analyses.
As in all PLP-enzymes, the coenzyme is bound through a Shiff
base with a lysine residue of the apoprotein, a complex called
internal aldimine that generates typical absorbance bands in the
visible region (Liang et al., 2019). Coenzyme binding to hOAT
gives rise to an absorbance band at 420 nm and a shoulder at
340 nm associated with positive dichroic signals, previously
attributed to the ketoenaminic and enoliminic tautomeric
forms of the Lys292 internal aldimine, respectively (Shen
et al., 1998; Montioli et al., 2017). As shown in Figures 2A,B,
the variants exhibited visible absorbance and CD spectra
qualitatively similar to those of the wild-type, although in
several cases they displayed a lower intensity of the
absorbance and/or dichroic signal. Their optical activity values
(Supplementary Table S3) were also comparable to that of 76
millidegree/A422nm of wild-type hOAT, thus suggesting that the
mutations do not significantly alter the microenvironment of the
internal aldimine. The only exception was the R154L variant
which exhibited an optical activity value ∼1.6-fold lower than that
of the wild-type enzyme indicating that in this variant the chiral
microenvironment of the cofactor is altered.
We acquired the near-UV CD (Figure 2B), as well as ANS and
intrinsic fluorescence emission (Figures 2C,D) spectra of the
TABLE 1 | Kinetic parameters of the overall transamination of hOAT wild-type and variants. Experiments were performed in 50 mM HEPES buffer pH 8.0, 150 mM NaCl, at
25°C in the presence of saturating PLP.
Enzyme Substrate Co-substrate kcat (s
−1) KM(L-Orn) (mM) KM(α-KG) (mM) kcat/KM (mM
−1s−1)
WT L-Orn α-KG 34.9 ± 0.6 6.5 ± 0.4 — 5.4 ± 0.3
α-KG L-Orn 35.7 ± 0.7 — 3.9 ± 0.5 9.1 ± 1.2
Q90E L-Orn α-KG 21.3 ± 0.4 3.6 ± 0.3 — 5.9 ± 0.5
α-KG L-Orn 19.2 ± 0.3 — 5.6 ± 0.2 3.4 ± 0.1
R154L L-Orn α-KG 0.1 ± 0.01 nd nd nd
α-KG L-Orn
G237D L-Orn α-KG 0.08 ± 0.01 nd nd nd
α-KG L-Orn
R271K L-Orn α-KG 12.9 ± 0.2 5.0 ± 0.3 — 2.6 ± 0.2
α-KG L-Orn 13.9 ± 0.2 — 6.5 ± 0.4 2.1 ± 0.1
E318K L-Orn α-KG 26.7 ± 1.4 4.4 ± 1.0 — 6.1 ± 1.4
α-KG L-Orn 26.7 ± 0.5 — 7.3 ± 0.5 3.7 ± 0.3
C394Y L-Orn α-KG 5.8 ± 0.4a 1.6 ± 0.2a — 3.6 ± 0.6a
α-KG L-Orn 5.8 ± 0.4 — 28.8 ± 2.4 0.20 ± 0.02
aData fitted to a non-hyperbolic curve taking into account substrate inhibition (Ki  9.7 ± 1.4 mM).
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enzymatic species under study. Near-UV and intrinsic
fluorescence spectra provide insights into possible changes of
the tertiary structure of hOAT, while ANS emission spectra give
information about changes of hydrophobic surfaces exposed to
the solvent. Taking into account the magnitude of the dichroic
signal, the emission intensity, and the maximum of the
fluorescence spectra of each variant with respect to the wild-
type, it can be inferred that changes consisting in a remarkable
alteration of the microenvironment of aromatic amino acids and
an increased exposure of hydrophobic surfaces are present on
Q90E and R271K, while they are appreciable at a different degree
for the remaining variants. The E318K species shows the less
pronounced alterations only consisting in a slight increase in the
ANS signal, while more evident spectral changes are observed for
the R154L, G237D and C394Y variants, suggesting a structural
defect. However, considering that these species also show active
site alterations translating into a catalytic defect, it is not possible
to establish if and to what extent the observed changes in tertiary
structure represent conformational changes in the
microenvironment of the active site. The quaternary structure
was also analyzed by SEC. All variants, except the R154L,
displayed a tetrameric assembly as previously observed for the
wild-type (Montioli et al., 2017) (Supplementary Figure S6). In
fact, the R154L variant exhibited an elution volume
corresponding to that of the artificial dimeric variant R217A
(Montioli et al., 2017) indicating that the R154L mutation affects
hOAT tetramerization. The proximity of the mutation site to the
tetramer interface highlighted by in silico analyses, could explain
the perturbation of the tetramer-dimer equilibrium. It should be
noticed that the different quaternary structure of the R154L
variant does not probably relate to its kinetic defect,
considering that the tetrameric assembly is not crucial for
hOAT catalysis (Montioli et al., 2017).
Taken together, these data indicate that 1) the R154L and
G237D variants display a predominant catalytic defect, in line
with the E. coli expression studies showing a strongly reduced
specific activity not paralleled by reduced protein levels; 2) the
Q90E and R271K variants exhibit a folding defect more
pronounced than a catalytic one. It should be noted that the
residues Gln90 and Arg271 are close to each other at the interface
between the N-terminal and large domain. The finding that their
mutation leads to the most prounced alterations in the hOAT
tertiary structure is in line with the low protein levels upon
expression in E. coli, suggesting a reduced efficiency of the folding
process probably driven by a conformational change of the loop
75–95 (Supplementary Figures S1A,D); 3) the E318K and
FIGURE 2 | Spectroscopic characterization of hOAT variants. Absorbance (A), UV-Vis CD (B), ANS fluorescence emission (C) and intrinsic fluorescence emission
spectra (D) of hOAT wild-type and the variants under study. The color code for all panels is reported as inset of panel A. Absorbance and CD spectra were registered at
6 μM enzyme concentration while ANS and intrinsic fluorecence were measured at 1 μM enzyme. CD and fluorescence analyses were performed in the presence of
exogeouns PLP. All measurements were performed in 50 mM HEPES pH 8.0, 150 mM NaCl.
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C394Y variants show a complex behavior. When expressed in
bacteria, the E318K shows a reduction of specific activity that
could be partly ascribed to the 23% reduction in kcat, and partly to
a conformational defect possibly promoting the formation of
insoluble aggregated species. In this regard, it is noteworthy that,
despite the high expression level in the soluble fraction of the
E. coli lysate, the purification yield of E318K resulted considerable
lower than those of the wild-type, R154L and G237D (Expression
and Purification of Mutants). This suggests that E318K could
partly undergoes aggregation or degradation during the
purification procedure. The C394Y appears to be affected by a
structural defect more pronounced than the E318K, in line with a
more remarkable reduction of protein levels in the bacterial
lysate, accompanied by a catalytic defect.
A possible conformational change caused by the Q90E,
R271K, E318K, and C394Y mutations in hOAT was
corroborated by limited proteolysis experiments. As shown
in Supplementary Figure S7, although all species exhibited a
similar proteolysis pattern, the variants were digested with
different rates as compared to the wild-type. In particular,
wild-type hOAT underwent the removing of a short amino acid
stretch generating a product with an apparent MW of 43 KDa,
which did not undergo any further degradation up to 50 min. A
qualitatively similar behavior was observed for the R271K,
E318K and C394Y variants, although the cleavage occurred
with a more rapid kinetics with respect to wild-type hOAT. A
different trend was observed for the Q90E variant, which
clearly exhibited a progressive degradation of both the
native and the cleaved species. These data agree with those
obtained in bacterial lysates and/or purified proteins
suggesting that the Q90E, R271K, E318K, and C394Y
variants are affected by a structural alteration, which is
more pronounced for the Q90E as compared to the other
variants. This change could possibly translate into an
FIGURE 3 | Analysis of hOAT variants expressed in Hek293-OAT_KO cells cultured in DMEMmedium. (A) BN-PAGE. Purified mitochondria were solubilized in the
presence of 1% DDM, centrifuged at 16,000 g for 20 min. The soluble fractions were run on a 3–12% Blue Native gel. The total OAT content of each sample under
denaturing conditions is also shown. An antibody against porin was used as loading control. (B) Relative OAT content evaluated by ImageJ sofware. (C) Transaminase
activity. 100 μg of soluble lysate was incubated with 100 mM L-Orn, 10 mM α-KG, and 200 μM PLP at 25°C in 50 mM HEPES buffer, pH 8, 150 mM NaCl. The
absorbance of pyrroline-5 carboxylate derivatized with aminobenzaldehyde was measured at 440 nm. Data represent the mean fo at least three independent
experiments.
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increased degradation propensity in a eukariotic cellular
environment (see below). Therefore, to identify the possible
cellular relapse of the folding defect, we decided to explore the
behavior of the Q90E, R271K, E318K, and C394Y variants in a
model base on cells of human origin.
Expression of Q90E, R271K, E318K, and
C394Y Variants in a Cellular Model of GA
We analyzed the behavior of the variants endowedwith a structural
defect in a cellular model of GA based on Hek293-OAT_KO cells
(Montioli et al., 2018) stably expressing each species by lentiviral
infection. As shown in Figure 3, in a high B6 medium (DMEM)
Q90E and R271K variants displayed specific activity and
expression levels reduced to less than 2% and 7–15%,
respectively, as compared to wild-type hOAT, and a tetrameric
assembly in BN-PAGE, in line with the results obtained with
purified proteins. The E318K variant showed protein levels in SDS-
PAGE similar to those of the wild-type, and a smear of oligomers
and high-order aggregates in BN-PAGE, with no defined bands
relatable to tetrameric species. Nevertheless, its specific activity was
only reduced by 27%, probably because of the increased stability of
the oligomers and aggregates in the assay mixture, where a lower
concentration and excess of substrate and coenzyme is present, as
FIGURE 4 | Analysis of hOAT variants expressed in Hek293-OAT_KO cells cultured in Ham’s F12 medium. Hek293-OAT_KO cells expressing each species were
growth for 4 days in Ham’s F12 medium and lysed in CHAPS buffer. (A) Transaminase activity. 100 μg of soluble lysate was incubated with 100 mM L-Orn, 10 mM
α-KG, and 200 μM PLP at 25°C in 50 mM HEPES buffer, pH 8, 150 mM NaCl. The absorbance of pyrroline-5 carboxylate derivatized with aminobenzaldehyde was
measured at 440 nm. Data are expressed as mean ± S.E.M. (n  3). (B) 10 μg of the soluble lysate were subjected to SDS-PAGE, immunoblotted with anti-OAT
from mouse (1:1,000), and detected by chemiluminescence. Data are expressed as mean ± S.E.M. (n  3). (C) Representative western-blot analysis of 10 μg of total
protein levels in the soluble and insoluble fraction. (D) Half-life determination by cycloheximide assay. The image shows representative western-blot analyses. For each
sample, the relative intensity with respect to that at the start of the chase was used to calculate the half-life. Data are the mean of two independent experiments. (E)
Changes in Q90E expression levels upon treatment with 10 μM MG132.
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compared with the BN-PAGE mixture. Finally, the C394Y variant
showed oligomeric assembly and protein levels similar to those of
the wild-type, but its specific activity was reduced to 3%, thus
confirming the occurrence of a functional alteration. The
correlation between a reduced specific activity and reduced
protein levels or altered assembly for the Q90E, R271K and
E318K variants allows to envisage a folding defect, in agreement
with E. coli expression studies. On the other hand, in the case of the
C394Y variant we observed a strongly reduced specific activity in
line with its catalytic defect, but we did not detect variations in
proteins levels as compared with wild-type hOAT. The latter
feature is different from what observed upon expression in
E. coli. It can be speculated that the expression levels of Hek293
cells are low enough to promote the folding of the variant in a
enriched culture medium through the action of molecular
chaperones.
To gain deeper insights into the behavior of each variant, we
studied their properties upon culturing cells in a medium containing
a B6 concentration of the same order of magnitude than that of
biological fluids (Ham’s F12) (Figures 4A,B). In agreement with the
data obtained in DMEM, Q90E and R271K displayed specific
activity and expression levels reduced by 125-fold and 18-fold,
respectively, as compared with wild-type hOAT. In the case of
Q90E, the expressionwas so low that we detected only a faint band in
western-blot (Figures 4A–C). E318K showed expression level and
specific activity similar to those of wild-type hOAT. Finally, C394Y
displayed a strong reduction of specific activity that is not paired by a
remarkably reduced expression level. Interestingly, by determining
the kinetic parameters of the transamination reaction in lysates of
cells expressing the C394Y variant (Supplementary Figure S5), we
confirmed the occurrence of a substrate inhibition phenomenon in
line with the demonstrated functional defect of the purified variant.
Notably, at the L-Orn concentrations present in GA patients, the
C394Y variant could be inhibited, a mechanism possibly
contributing to pathogenesis.
By a deeper investigation of the intracellular behavior of wild-
type hOAT in Ham’s F12 medium (Figure 4C) we found that 1)
more than 90% of the wild-type was present in the soluble fraction;
2) the reduced protein levels of the Q90E and R271K variants were
not due to an increased amount of insoluble protein; 3) the E318K
variant showed subtle differences with respect to the wild-type
consisting in a barely detectable increase in the relative amount of
protein present in the insoluble fraction, the appearance of
aggregates in western-blot upon long exposure (data not
shown), and the presence of a slightly higher proportion of
high MW species in cross-linking experiments that was not
possible to quantify (Supplementary Figure S8). In addition,
wild-type hOAT was endowed with a high intracellular stability,
as shown by its half-life higher than 72 h similar to that reported for
other mitochondrial proteins (Stotland and Gottlieb, 2015). On the
other hand, in line with the limited proteolysis experiments on
purified proteins, the R271K, E318K, and C394Y variants showed a
reduced intracellular half-life (Figure 4D), being the R271K and
the C394Y the most prone to be degraded. Mitochondria have a
specific set of quality control systems, made up of proteases and
molecular chaperones, which handle both internally-produced and
nuclear-encoded proteins (Voos et al., 2016). Damaged proteins
are targeted for degradation insidemitochondria, or, if homeostasis
cannot be restored, through removal of damaged mitochondria by
mitophagy (Stotland and Gottlieb, 2015). Thus, pathogenic hOAT
variants showing conformational alterations could be more prone
to be recognized by the mitochondrial quality control systems and
to be directed to degradation. Although the reduction of half-life
cannot be taken as a parameter to quantify the degree of
conformational alteration of a variant, it should be noted that
the E318K is the most stable. This is in line with clinical data on
homozygous or compound heterozygous GA patients bearing the
E318K mutation, where it has been observed a mild phenotype,
with some indications of gene dosage effects (Mashima et al., 1999).
As for the Q90E variant, we could not determine its half-life
due to the low expression levels. Nevertheless, we obtained
indirect evidence for its propensity to proteolytic degradation
by the finding that treating cells expressing the variant with
MG132 caused a significant increase in protein levels
(Figure 4E). Although the turnover of some mitochondrial
precursor proteins occurs before reaching the mitochondrial
compartment (Radke et al., 2008; Bragoszewski et al., 2013),
MG132 is also able to inhibit mitochondrial proteolytic
enzymes (Smith and Schnellmann, 2012; Ajit Bolar et al.,
2013). Thus, the degradation inside mitochondria is the most
probable explanation of the data. Nonetheless, since the Gln90
mutation could prevent hOAT mitochondrial import, we
performed immunofluorescence microscopy experiments to
define the subcellular localization of Q90E. These experiments
confirmed the very low expression levels of the variant, but
showed that it correctly localizes inside mitochondria
(Supplementary Figure S9), as also indicated by the presence
of a band in western-blot corresponding to the mature protein. In
this regard, Kobayashi et al. (1995) have reported experiments in
insect cells where the Q90E variant was present as a 49 kDa
precursor and was not imported to mitochondria. This
discrepancy can be understood considering that the human
and insect mitochondrial import machinery and quality
control systems are different, and that insect cells give rise to
very high protein expression levels (Yee et al., 2018). Indeed, the
same authors did not find the precursor band when the variant is
expressed in mammalian cells (Kobayashi et al., 1995). Therefore,
it cannot be excluded that the Gln90 mutation could interfere
with the import kinetics and promote the degradation of the
variant in the cytosol. A similar process has been already observed
for a pathogenic form of the cytochrome c oxidase assembly
factor 7 (Mohanraj et al., 2019).
Altogether, the picture coming from the combination of
protein and cell studies confirms that the folding-defective
pathogenic variants display detectable deviations from the
behavior of hOAT wild-type and that the changes are less
pronounced in a variant associated with a mild phenotype, the
E318K, thus supporting the reliability of our experimental model.
Effect of B6 Vitamers Treatment on Q90E,
R271K, E318K, and C394Y Variants
One of the treatment options available to GA patients is the
administration of Vitamin B6, which aims at increasing the
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intracellular concentration of PLP (Ramesh et al., 1988;
Kennaway et al., 1989; Heller et al., 2017). It has been
suggested that responsive patients bear mutations that preserve
hOAT activity, and that the coenzyme could stabilize the protein
by promoting holoenzyme formation (Kennaway et al., 1980;
Ramesh et al., 1988; Kennaway et al., 1989). The analysis of the
behavior of the wild-type enzyme has shown that in the absence
of PLP it displays a less stable tetrameric assembly and is more
prone to undergo aggregation under physiological conditions
(Montioli et al., 2017). On these bases, the possibility that PLP
could act as a chaperone for hOAT, as already observed for other
disorders involving PLP-enzymes (Oppici et al., 2016), can be
raised.
We tested the responsiveness of the Q90E, R271K, E318K,
and C394Y variants by comparing their expression level and
specific activity upon culturing cells for 1 week (a time sufficient
to reach equilibrium in preliminary time course experiments) in
Ham’s F12 medium in the absence or presence of vitamin B6. In
particular we tested both the vitamers used in clinics, pyridoxine
(PN), and the other two present in nature, pyridoxamine (PM)
and pyridoxal (PL) (Albersen et al., 2014), all at 10 μM
concentration. As shown in Figure 5A, B6 vitamers did not
affect the overall protein expression levels and specific activity of
hOAT wild-type and of the pathogenic variants. In this regard,
although we could observe a slight increase in the specific
activity of Q90E in the presence of PN and of R271K in the
presence of PN or PM, the differences did not reach statistical
significance (Figure 5B). This result was surprising, since
although the clinical responsiveness of GA patients bearing
the Q90E mutation is presently unknown, three patients
bearing the E318K were found to be responsive (Mashima
et al., 1999).
Thus, in our cellular model of GA, folding-defective
pathogenic variants seem insensitive to coenzyme
administration, apparently in contrast with clinical data. A
discrepancy between clinical and in vitro data has been also
observed in studies performed using yeast expression systems or
patient fibroblasts (Doimo et al., 2013), and it merits some
considerations. First, it should be mentioned that we could not
adapt Hek293-OAT_KO cells for growing in a B6-free medium,
which would have possibly allowed to maximise the effect of
vitamin B6 addition, because of a low cell viability in the absence
of PN. Second, all utilized in vitro models do not recapitulate the
physiology of the retinal pigment epithelium, where the hOAT
deficit gives rise to clinically-relevant changes. Thus, it can be
hypothesized that human cell lines or yeast are suitable to analyze
the consequences of missense mutations on the hOAT
intracellular behavior, but are not sensitive enough to detect
changes caused by coenzyme administration. However, it cannot
be excluded that the B6-responsiveness of GA patients could be
also due to molecular mechanisms independent of hOAT, such as
to the promotion of alternative pathways of L-Orn degradation
dependent on PLP. In this regard, studies performed on other
mitochondrial PLP-enzymes in the purified form have evidenced
that their folding is not promoted by the coenzyme (West and
Price, 1990). By comparing the refolding of the cytosolic and
mitochondrial isoenzymes of aspartate aminotransferase, it has
been evidenced that, notwithstanding their high levels of
sequence identity and structural similarity, they show an
opposite behavior in refolding studies. While the cytosolic
enzyme shows reversible unfolding in the presence of PLP, the
mitochondrial counterpart is not able to refold even in the
presence of the coenzyme (West and Price, 1990). Needless to
say, more detailed studies on both the folding process of purified
hOAT and the role of the coenzyme are necessary to shed light on
this issue.
CONCLUSION
In rare diseases associated with the malfunction of a protein, any
pathogenic variant might show alteration of different functional
or structural properties. This complicates the analysis of the
underlying origin of diseases and, as a consequence, impairs a
FIGURE 5 | Effect of vitamers B6 on expression level and specific activity of OAT species in Hek293-OAT_KO cells. Hek293-OAT_KO cells overexpressing the
indicated hOAT variants were growth for 7 days in Ham’s F12 medium in the absence (−) or presence (+) of the indicated vitamers B6 at 10 μM concentration. (A) 20 μg
of the soluble lysate were subjected to SDS-PAGE, immunoblotted with anti-OAT frommouse (1:1,000), and detected by chemiluminescence. The images come from a
single Western-blot and are representative of at least two independent experiments. (B) Transaminase activity was detected by incubating 100 μg of soluble lysate
with 100 mM L-Orn, 10 mM α-KG, and 200 μM PLP at 25°C in 50 mM HEPES buffer, pH 8, 150 mM NaCl. Bar graphs represent mean ± S.E.M. of four independent
experiments. C stands for the untreated control.
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specific therapeutic approach. This is true in GA, where the
detailed functional/structural effect(s) of most disease-causing
mutations at protein level, i.e., the enzymatic phenotype, are
presently unknown, with the exception of the V332M and R180T
variants. Here, we tried to expand the spectrum of the enzymatic
phenotypes leading to the hOAT deficit by defining the effects of
representative missense mutations identified in homozygous
patients, and involving residues located in different hOAT
domains. Our data indicate that 1) the R154L and G237D
mutations give rise to a remarkable loss of catalytic activity,
which is probably the main responsible for pathogenicity; 2) the
Q90E and R271K mutations cause a folding defect leading to a
reduced intracellular half-life, which leads to a hOAT deficit
because it reduces the amounts of functional protein; 3) the
E318K and C394Y variants are endowed with a combination of
functional and structural defects. The E318K mutation gives rise
to mild kinetic alterations and a slight folding defect that mainly
translates into a reduced hOAT half-life, in line with the milder
phenotype of GA patients bearing this mutation (Mashima et al.,
1999). In the C394Y variant, the folding defect is also
accompanied by a functional alteration consisting into a
substrate inhibition phenomenon that possibly contributes to
pathogenicity. In contrast with clinical data, even if in limited
number, we also found that Vitamin B6 is not able to induce a
significant rescuing effect in none of the GA-associated mutations
causing folding defects in hOAT. The latter finding opens the
question on the distinction in B6-responsive and non-responsive
GA patients (Montioli et al., 2021) and the search of other
approaches aiming at counteracting misfolding for hOAT
variants showing folding defects. Overall, these results allow us
to expand the understanding of the molecular basis underlying
GA pathogenesis as necessary premise for the establishment of
genotype/phenotype correlations, an important gap of knowledge
for this disorder.
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